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Research
Bisphenol A (BPA) is a synthetic compound 
that is suspected to act as an endocrine dis-
ruptor (i.e., a compound capable of causing 
dysfunction to hormonally regulated body sys-
tems) (Talsness et al. 2009). It was originally 
synthesized as a synthetic estrogen (Dodds 
and Lawson 1936). It is used extensively as 
a monomer in polycarbonate plastics and in 
the epoxy resins that are used to line food 
and beverage containers and is one of the 
world’s highest-production-volume chemi-
cals (Ritter 2011). Ubiquitous exposure to 
BPA is believed to occur mainly through the 
diet, with additional contributions from den-
tal sealants, dermal exposure, and inhalation 
of household dusts. BPA metabolites have 
been reported in the urine of > 90% of people 
in representative population samples in the 
United States and Europe (Calafat et al. 2008; 
Galloway et al. 2010).
Whether BPA can cause human health 
effects is a matter of some debate. There 
has been concern about the potential for a 
relation  ship between BPA and negative health 
effects, including increases in abnormal penile/
urethra develop  ment in males, early sexual 
maturation in females, an increase in neuro-
behavioral problems such as attention deficit–
hyperactivity disorder (ADHD) and autism, 
an increase in childhood and adult obesity and 
type 2 diabetes, and an increase in hormon-
ally mediated cancers, such as prostate and 
breast cancers (reviewed by Hengstler et al. 
2011; vom Saal et al. 2007). Cross-sectional 
epidemiological studies have shown higher 
BPA exposure to be associated with adverse 
health effects in the general adult population. 
In a study of 1,455 respondents in the 2003–
2004 U.S. population-representative National 
Health and Nutrition Examination Survey 
(NHANES), higher urinary BPA concentra-
tions were associated with cardio  vascular dis-
ease diagnoses and with diagnosed diabetes 
but not with other common diseases, suggest-
ing specificity of the reported findings (Lang 
et al. 2008). In a further study of data from 
NHANES 2005/2006, higher BPA concen-
trations were again associated with coronary 
heart disease, providing independent repli-
cation of the findings (Melzer et al. 2010). 
Higher exposure to BPA has also been associ-
ated with reproductive and develop  mental 
abnormalities. In a study of 249 mothers and 
their children, prenatal urinary BPA concen-
trations in mothers were prospectively associ-
ated with externalizing behavior scores among 
their children when measured at 2 years of 
age (Braun et al. 2009). A positive association 
was also shown between BPA exposure and 
recurrent miscarriage in a prospective study of 
67 women (Sugiura-Ogasawara et al. 2005). 
The mechanisms under  lying these potential 
health effects remain to be determined.
Most studies of the health effects of 
BPA have focused on its estrogenic activity 
because it is widely documented to function 
as an agonist of certain estrogen receptors 
(ERs) (Lee et al. 2003) and as an androgen 
antagonist and to suppress aromatase activity 
(Bonefeld-Jørgensen et al. 2007). Additional 
receptor-mediated biological activities, includ-
ing binding to the orphan estrogen-related 
receptor ERRγ (Okada et al. 2008), thyroid 
hormone disruption (Moriyama et al. 2002), 
altered pancreatic β-cell function (Ropero 
et al. 2008), and obesity-promoting effects 
(Newbold et al. 2008), have been reported 
in different model systems. Many of these 
effects are already detectable in the nano-
molar range, prompting calls for a revision 
to the current tolerable daily intake (TDI) of 
50 μg/kg/day. However, until now, there has 
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Ba c k g r o u n d: Bisphenol A (BPA) is a synthetic estrogen commonly used in polycarbonate plastic and 
resin-lined food and beverage containers. Exposure of animal and cell models to doses of BPA below 
the recommended tolerable daily intake (TDI) of 50 μg/kg/day have been shown to alter specific 
estrogen-responsive gene expression, but this has not previously been shown in humans.
oB j e c t i v e: We investigated associations between BPA exposure and in vivo estrogenic gene expres-
sion in humans.
Me t h o d s : We studied 96 adult men from the InCHIANTI population study and examined in vivo 
expression of six estrogen receptor, estrogen-related receptor, and androgen receptor genes in 
peripheral blood leukocytes.
re s u l t s: The geometric mean urinary BPA concentration was 3.65 ng/mL [95% confidence inter-
val (CI): 3.13, 4.28], giving an estimated mean excretion of 5.84 μg/day (95% CI: 5.00, 6.85), 
significantly below the current TDI. In age-adjusted models, there were positive associations 
between higher BPA concentrations and higher ESR2 [estrogen receptor 2 (ER beta)] expression 
(unstandardized linear regression coefficient = 0.1804; 95% CI: 0.0388, 0.3221; p = 0.013) and 
ESRRA (estrogen related receptor alpha) expression (coefficient = 0.1718; 95% CI: 0.0213, 0.3223; 
p = 0.026): These associations were little changed after adjusting for potential confounders, includ-
ing obesity, serum lipid concentrations, and white cell sub  type percentages. Upper-tertile BPA 
excretors (urinary BPA > 4.6 ng/mL) had 65% higher mean ESR2 expression than did lower-tertile 
BPA excretors (0–2.4 ng/mL).
co n c l u s i o n s: Because activation of nuclear-receptor–mediated pathways by BPA is consistently 
found in laboratory studies, such activation in humans provides evidence that BPA is likely to 
function as a xenoestrogen in this sample of adults.
key w o r d s : bisphenol A, endocrine disruption, estrogen receptor-β, estrogen-related receptor-α, 
human biomonitoring, InCHIANTI, toxicogenomics. Environ Health Perspect 119:1788–1793 
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been no evidence that BPA at these low levels 
exerts significant biological effects in humans, 
and hence the TDI has remained unaltered 
(European Food Safety Authority 2010).
A recent cross-sectional examination 
of circulating sex hormone concentrations 
in 307 men showed higher BPA levels to be 
associated with changes in total testosterone 
concentrations [β = 0.046; 95% confidence 
interval (CI): 0.015, 0.076; p = 0.004 in fully 
adjusted models] (Galloway et al. 2010). There 
was no significant trend in 17β-estradiol lev-
els with higher BPA in men, although an 
earlier study of 167 men recruited through 
an infertility clinic used multiple adjusted 
regression models to show BPA concentra-
tions in urine to be inversely associated with 
the estradiol:testosterone ratio (Meeker et al. 
2010). Plausible explanations for these endo-
crine changes include altered expression of 
hormone-responsive genes. To date there is no 
in vivo evidence for changes in sex-hormone–
responsive gene expression associated with 
human exposure to BPA.
Here, we aimed to test the hypothesis that 
exposure to BPA would be associated with 
changes in the in vivo expression of estrogen- 
and androgen-responsive genes. To do this, we 
conducted a cross-sectional study to character-
ize six candidate estrogen- or androgen-related 
transcripts for differential in vivo expression in 
response to BPA exposure. The study popula-
tion was selected from the InCHIANTI study, 
a large European population representative 
sample based in Chianti, Italy.
Materials and Methods
Study population. The InCHIANTI study, a 
prospective population-based study of Italian 
adults (InCHIANTI 2011), was designed 
to identify risk factors for mid- and late-life 
morbidity in urban and rural populations 
and has been described extensively elsewhere 
(Ferrucci et al. 2000). InCHIANTI is per-
formed in two sites: Greve in Chianti (11,709 
inhabitants) and Bagno a Ripoli (Village of 
Antella, 4,704 inhabitants). The final study 
population included 1,453 persons (age range 
20–102 years) stratified across age ranges using 
a multi  stage sampling process, with a response 
rate of 91.6% from the baseline interview. 
Subjects and specimens selected for the pres-
ent study were those with the most adequate 
RNA and urine specimens in the 2008/2009 
follow-up, and ≤ 76 years of age, in line with 
previous work. Women were excluded from 
this analysis because of cyclic hormonal varia-
tions in pre  menopausal subjects. The Instituto 
Nazionale Riposo e Cura Anziani Institutional 
Review Board (Florence, Italy) provided ethi-
cal approval. All participants gave informed 
(or surrogate) consent.
Sample collection. Participants who con-
sented to give a blood sample were also asked 
to provide a spot morning urine sample, which 
was stored at –20°C until further analy  sis. First 
thing in the morning on the day of the study 
visit, after participants had been sedentary for 
15 min, fasting blood samples were collected 
for routine blood examination, and periph-
eral blood specimens preserving in vivo RNA 
expression were collected using PAXgene tech-
nology (Debey-Pascher et al. 2009).
Analysis of urinary BPA concentrations. 
Samples were analyzed at the Brixham 
Environmental Laboratory Division of 
Analytical Chemistry (a division of AstraZeneca 
PLC; Brixham, UK) in compliance with Good 
Laboratory Practice, EU Directive 88/32/
EEC (United Kingdom 2004). BPA ingested 
in humans is almost completely metabolized 
and rapidly excreted, so urine is considered 
the most appropriate matrix for assessment of 
exposure (Calafat et al. 2005). As part of our 
extensive Good Laboratory Practice–compliant 
quality control, we included reagent blanks 
and confirmed that samples stored for up to 
10 years contained predominantly metabo  lized 
compound, confirming minimal leaching of 
BPA from collection or storage vessels during 
this time. BPA concentrations were meas  ured in 
spot urine samples by liquid chromatography–
mass spectrometry. Total (free and conjugated) 
urinary concentrations of BPA were obtained 
using online, solid-phase extraction coupled 
with high-performance liquid chromatography–
isotope dilution tandem mass spectrometry 
with peak focusing, as described previously 
(Galloway et al. 2010). Calibration was linear 
from 0.50 to 100 μg/L (R2 > 0.996), limit of 
detection was < 0.50 ng/mL BPA, the limit 
of quantification was 0.50 ng/mL BPA, and 
the lowest calibration standard gave a signal 
height:noise ratio > 10 (relative standard 
deviations < 20%, all other standards < 15%).
Gene expression by real-time reverse-
  transcriptase polymerase chain reaction 
(RT-PCR). Blood leukocytes were used for 
transcript analysis because they are convenient 
and available and because they provide suf-
ficient power in large cohorts where access 
to other tissues is lacking. Because BPA 
is metabolized in the intestines and liver to 
form predominantly BPA-monoglucuronide, 
which is passed through the bloodstream to 
the kidney, exposure of leukocytes to BPA 
and/or its metabolites is inevitable. To test 
the hypothesis that exposure to BPA would 
be associated with changes in the expression 
of estrogen- and androgen-responsive genes, 
we correlated BPA levels as a continuous trait 
with the expression of ER, androgen receptor 
(AR), and estrogen-related receptor (ERR) 
genes by quantitative real-time PCR in a sub-
set of 100 male subjects. These genes were 
chosen because the nuclear hormone receptors 
they encode are transcription factors that con-
trol essential develop  mental and physiological 
pathways and because activation of these 
nuclear-receptor–mediated pathways by BPA 
is consistently found in laboratory studies.
Total RNA (100 ng) was reversed tran-
scribed in 20 μL reactions using the Superscript 
III VILO kit (Invitrogen, Paisley, UK), accord-
ing to the manufacturer’s instructions.
The expression levels of ESR1 (estrogen 
receptor 1; ERα), ESR2 [estrogen recep-
tor 2 (ER beta); ERβ], ESRRA (estrogen 
related receptor alpha; ERRα), ESRRB (estro-
gen related receptor beta; ERRβ), ESRRG 
(estrogen related receptor gamma), and AR 
(androgen receptor) genes were then assessed 
relative to the endogenous control genes GUSB 
(glucuronidase, beta) and ACTB (actin, beta; 
β-actin) on the TaqMan Low Density Array 
(TLDA) platform (Applied Biosystems, Foster 
City, CA, USA). Probes were inventoried 
with Applied Biosystems assays Hs01046812_
m1, Hs01100358_m1, Hs01584024_m1, 
Hs00155006_m1,  Hs00907244_m1, 
Hs99999908_m1, and Hs03023943_g1 for 
ESR1, ESR2, ESRRB, ESRRG, AR, GUSB, 
and ACTB genes, respectively. These probes 
were chosen because they are documented to 
pick up all isoforms and splice variants for the 
genes of interest.
The expression of the ESRRA gene was 
assessed by the use of a custom assay (probe 
and primer sequences available on request). 
Reaction mixes included 50 μL 2× TaqMan 
universal master mix (no AMPerase; Applied 
Biosystems), 40 μL distilled H2O, and 10 μL 
cDNA template per TLDA loading port. 
PCR amplifications were performed on the 
ABI 7900HT platform (Applied Biosystems). 
Cycling conditions were 50°C for 2 min, 
94.5°C for 10 min followed by 40 cycles 
of 97°C for 30 sec and 57.9°C for 1 min. 
The expression of each gene was measured 
in triplicate for each sample. Gene expres-
sion relative changes were quantified using 
the 2–ΔΔCt method (Livak and Schmittgen 
2001) relative to the geometric mean of the 
endogenous controls listed above using the 
StatMiner relative quantification software for 
high-throughput integrated analysis of TLDA 
data (Integromics, Grenada, Spain).
Statistical analysis. We assessed the asso-
ciation of candidate gene expression levels 
with urinary BPA concentration by multi-
variable linear regression. Data were adjusted 
for potential confounding factors that could 
influence BPA exposure or candidate gene 
expression: age (reported in years at the last 
birthday and used as a continuous variable); 
body mass index (BMI) calculated as weight 
in kilograms divided by height in meters 
squared; waist circumference (as a continu-
ous trait); highest level of education attained 
(in four categories: none/elementary, second-
ary, high school, and university/professional); 
low-density lipoprotein (LDL) cholesterol Melzer et al.
1790  v o l u m e  119 | n u m b e r 12 | December 2011  •  Environmental Health Perspectives
(milligrams per deciliter); triglycerides (milli-
grams per deciliter); and study site [individu-
als were drawn from a rural village (Greve) 
and an urban population (Bagno a Ripoli)]. 
Models were also adjusted for the percentage 
of neutrophils (neutrophil%), lymphocytes 
(lymphocyte%), monocytes (monocyte%), 
and eosinophils (eosinophil%) [the percent-
age of basophils (basophil%) was not added 
because the cell subtype percentages would 
have equaled 100%].
The expression value of each of the target 
genes was not normally distributed, and we 
used natural log transformation when gene 
expression was considered as a dependent 
variable. In all analyses, an upper age cut-
off was 76 years to minimize the problem of 
comorbidity. Data analysis was performed 
using STATA (version 10 SE; StataCorp LP, 
College Station, TX, USA); p < 0.05 was con-
sidered significant.
We used generalized additive mod-
els with penalized cubic regression splines 
(Wood 2006) to explore the functional form 
of the relationship between candidate gene 
expression levels and urinary BPA concentra-
tion. Linearity of the relationship between 
log-transformed expression level and log-
transformed BPA concentration was assessed 
by visual inspection of the estimated spline 
functions and by examining the estimated 
degrees of freedom (edf) for the smoothed 
BPA term. Values of the edf close to 1 were 
taken as evidence of linearity. Adjustment 
was made for the same potential confounding 
factors that were included in the multi  variable 
linear regression models. The prediction error 
criterion for smoothness selection was gen-
eralized cross-validation. Robustness of the 
smoothness selection was assessed by making 
comparisons with the use of maximum likeli-
hood estimation. The spline models were fit-
ted using R statistical software using the mgcv 
package for generalized additive modeling 
(version 2.12.1; R Project for Statistical 
Computing 2010). 
Results
The sample (n = 96; Table 1) had a mean age 
of 58.3 years (range, 32–76 years) and a mean 
(± SD) BMI of 27.8 ± 4.1 kg/m2. The geo-
metric mean urinary BPA concentration was 
3.65 ng/mL (95% CI: 3.13, 4.28) ranging 
from 0.73 to 56.94 ng/mL (limit of detection 
< 0.5 ng/mL). The distribution was skewed, 
with a 10th percentile of 1.3 ng/mL and a 
90th percentile of 10.4 ng/mL. The estimated 
mean excretion was 5.84 μg/day (95% CI: 
5.00, 6.85).
The expression of transcripts associated with 
sex-hormone–related signaling was quantified 
by real-time RT-PCR (Table 2). Expression 
of ESRRG was not detected in our samples. 
There was only one significant correlation of 
expression intensities between probes: between 
ESR1 and ESR2 (pairwise correlation = 0.24; 
p = 0.02). We obtained valid expression inten-
sity measures for 96 men for the ESR2 gene 
and 83 men for the ESRRA gene (Table 2). 
BPA concentrations in the 96 respondents with 
successful ESR1 expression measures were no 
different from the remaining 55 respondents 
< 76 years of age (age-adjusted regression with 
log-transformed BPA concentration: unstan-
dardized linear regression coefficient = 0.012; 
95% CI: –0.114, 0.138; p = 0.848) for which 
meas  ured BPA values were available. 
Using urinary BPA concentrations as 
a continuous variable, we tested linear asso-
ciations between BPA and gene expression. 
In age-adjusted regression models of log-
transformed BPA concentrations against 
log-transformed expression levels (Table 3), 
we observed positive associations with ESR2 
(ERβ; coefficient = 0.1804; 95% CI: 0.0388, 
0.3221; p = 0.013) and ESRRA (ERRα, coef-
ficient = 0.1718, 95% CI: 0.0213, 0.3223, 
p = 0.026) but not with ESR1(ERα), 
ESRRB(ERRβ), or AR. 
In models additionally adjusted for previ-
ously suggested confounders (Sharpe 2010) 
(BMI, LDL cholesterol and triglyceride 
concentrations, study site, and educational 
attainment—a proxy for social position) and 
white cell subtype percentages, the results were 
little changed: for ESR2, coefficient = 0.1387; 
95% CI: 0.001, 0.2764; p = 0.048; for ESRRA 
coefficient = 0.1886; 95% CI: 0.0324, 0.3448; 
p = 0.019) (Table 4). 
When using an alternative exposure metric 
of dividing BPA concentrations into tertiles 
in the fully adjusted models (Figure 1), par-
ticipants in the lowest BPA exposure tertile 
had a geometric mean expression of ESR2 
of 0.80 IU (95% CI: 0.65, 0.99), rising to 
1.32 IU (95% CI: 1.08, 1.60) in the highest 
tertile, a 65% increase in mean expression. 
For ESRRA, the same measures were 0.66 IU 
(95% CI: 0.49, 0.89) and 0.91 IU (95% CI: 
0.78, 1.06), a 38% increase in mean expres-
sion of the gene.
Figure 2A shows a spline plot for the 
change in natural log of ESR2 expression as 
a function of log-transformed urinary BPA 
concentration. This suggests that the posi  tive 
association between ESR2 and BPA concen-
tration is curvilinear (edf = 1.45; p-value for 
smoothed term = 0.027), with evidence of 
a diminishing effect as BPA concentration 
increases. A similar spline plot for ESRRA 
expression is shown in Figure 2B. This sug-
gests that the relationship with BPA con-
centration is linear for this ERR (edf = 1.00; 
p‑value for smoothed term = 0.017).
Table 1. Characteristics of the sample (n = 96).
Characteristic Mean ± SD (range)a
Age (years) 58.3 ± 15.2 (32–76)
Site (%)
Greve 38.4
Bagno a Ripoli 61.5
Education (%)
None/elementary 22.9
Secondary school 26.0
High school 35.4
Professional/university 16.6
BMI (kg/m2) 27.8 ± 4.1 (18.38–42.99)
LDL cholesterol (mg/dL) 125.4 ± 29.8 (60–220)
Triglycerides (mg/dL) 137.3 ± 75.3 (45–469)
Neutrophils% 55.2 ± 9.7 (26.2–79.1)
Lymphocytes% 32.8 ± 9.2 (9.1–59.9)
Monocytes% 8.4 ± 2 (4.3–21.3)
Eosinophils% 3 ± 1.7 (0.1–10.3)
Basophils% 0.5 ± 0.2 (0.1–1.4)
aValues shown are mean ± SD (range) except where 
indicated. 
Table 2. Expression characteristics of the tested estrogen and androgen target genes.
Target gene Assay IDa Accession numberb n Mean ± SD (range)
ESR1 Hs01046812_m1 NM_000125 96 1.21 ± 0.535 (0.365–3.165)
ESR2 Hs01100358_m1 NM_001040275 96 1.294 ± 0.899 (0.167–5.585)
ESRRA Hs01067166_g1 NM_004451 83 0.882 ± 0.33 (0.105–1.991)
ESRRB Hs01584024_m1 NM_004452 96 2.974 ± 2.434 (0.000–10.363)
ESRRG Hs00155006_m1 NM_206595 Not expressed
AR Hs00907244_m1 NM_000044.2 96 1.232 ± 0.673 (0.188–3.295)
aTaqMan Gene Expression assay identification number. bAccession numbers from the National Center for Biotechnology 
Information (2011). 
Table 3. Estimates for the associations between natural log of urinary BPA concentrations and gene 
expression intensity (log transformed), in age-adjusted and fully adjusteda regression models.
Age-adjusted model Fully adjusted model
Gene Coefficient (95% CI) p-Value Std β Coefficient (95% CI) p-Value Std β
ESR1 –0.0657 (–0.1815, 0.0500) 0.262 –0.117 –0.1071 (–0.2205, 0.0063) 0.064 –0.1909
ESR2 0.1804 (0.0388, 0.3221) 0.013 0.231 0.1387 (0.001, 0.2764) 0.048 0.1775
ESRRA 0.1718 (0.0213, 0.3223) 0.026 0.250 0.1886 (0.0324, 0.3448) 0.019 0.2699
ESRRB –0.2816 (–1.3969, 0.8337) 0.617 –0.054 –0.4857 (–1.6669, 0.6955) 0.416 –0.0925
ESRRG ND ND
AR 0.0115 (–0.1404, 0.1634) 0.881 0.016 0.0925 (–0.0646, 0.2495) 0.245 0.1285
Abbreviations: ND, not detected; Std, standardized.
aFull adjustment included age, BMI, study site, educational attainment, and LDL cholesterol and tri  glyceride concentra-
tions, plus percentages of neutrophils, lymphocytes, monocytes, and eosinophils. Bisphenol A and gene expression in vivo
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Discussion
In this study, we aimed to assess whether 
increased urinary BPA concentrations were 
associated with changes in gene expression 
in vivo in the general adult population. We 
made use of a large-scale and high-quality pop-
ulation-representative data set for which speci-
mens preserving in vivo RNA expression were 
available. We were able to measure in vivo 
expression of five ER, ERR, and AR genes in 
peripheral blood leuko  cytes in 96 adult men. 
Using urinary BPA excretion as a marker of 
exposure, we found that those with higher 
BPA exposures had higher expression of two 
estrogen-responsive genes, ESR2 (ERβ) and 
ESRRA (ERRα).
These findings are important because they 
suggest that BPA is bioactive in the human 
body and that associations with hormone sig-
naling and related disorders are biologically 
plausible. ERβ, which showed the strongest 
association with BPA exposure, is one of two 
ER subtypes that, along with ERα, medi-
ates the physiological actions of estrogens 
(Swedenborg et al. 2009). ERβ and ERα have 
distinct tissue distribution, ligand specificities, 
and functions; ERα is predominant in the reg-
ulation of female reproduction, whereas ERβ 
is important in maintaining the structure and 
function of non  classic target tissues, including 
prostate, colon, and cardio  vascular and central 
nervous systems (Imamov et al. 2005). BPA 
displays estrogenic agonist activities against 
both ERα and ERβ subtypes in vitro, with 
relatively high ERβ selectivity (Matthews 
et al. 2001), consistent with our findings. The 
modulation by BPA of ER gene expression 
has previously been shown in animal mod-
els, at environmentally relevant concentra-
tions. For example, exposure of rat prostate 
mesenchyme cells to 1 nM BPA led to altered 
ER gene expression, accompanied by modest 
stimulation of cell growth, with a threshold 
of induction around 30-fold less potent than 
17β-estradiol (Richter et al. 2007).
ERRα belongs to the NR3B orphan 
nuclear receptor subgroup, which consists of 
ERRα, ERRβ, and ERRγ (Hong et al. 1999). 
All three ERRs show close sequence identity 
to the ERα DNA binding domain and also 
feature a conserved C-terminal domain with 
a putative ligand binding domain and inter-
action surfaces for coregu  la  tors, and a less con-
served N-terminal domain (Giguère 2002). 
Despite this close structural homology to the 
ERs, estradiol does not bind to ERRα, and 
X-ray crystallography of the putative ligand-
binding domain pocket of ERRα shows it to 
be almost completely occupied by side chains. 
This supports the suggestion that ERRα shows 
ligand-independent transcriptional activa-
tion and is largely dependent on its functional 
interaction with coregulators, including peroxi-
some proliferator-activated receptor-γ (PPARγ) 
coactivator 1α (PGC-1A) and PGC-1B for 
optimal gene regulation (Ranhotra 2010). In 
adults, ERRα is constitutively expressed in tis-
sues that preferentially use fatty acids as energy 
sources, including adipose tissue, heart, and 
skeletal muscle, where it plays a significant role 
in regulating energy homeo  stasis and adaptive 
oxidative capacity (Dufour et al. 2007). These 
functions are thought to involve close coopera-
tion with PGC-1A and ERRγ (Villena and 
Kralli 2008). Crucially, BPA binds to ERRγ 
with high affinity (Okada et al. 2008), and 
ERβ has been identified as an important regu-
lator of PPARγ (Foryst-Ludwig et al. 2008).
Given the structural homology between 
ERs and ERRs, particularly in the DNA-
binding domain, involvement of ERRs in 
estrogenic signaling pathways is not unex-
pected (Giguère 2002). ERRα has been 
proposed as a regulator of aromatase activ-
ity (Yang et al. 1998), and in turn, estradiol 
induces up-regulation of ERRα in some tis-
sues (Shigeta et al. 1997). ERRα stimulation 
of androgen-responsive element–containing 
promoters illustrates the potential for cross-
talk with signaling driven by other steroid 
hormones (Teyssier et al. 2008).
The functional relevance of changes in 
ERβ and ERRα expression in blood leuko-
cytes has not been determined. Because estro-
gens and androgens can exert differential 
effects in function depending on the cell type 
and its stage of development, the consequences 
Table 4. Multiple regression model estimates for the associations between explanatory variables and natural logs of ESR2 and ESRRA gene expression.
ESR2 ESRRA
Variable Coefficient (95% CI) p-Value Std β Coefficient (95% CI) p-Value Std β
BPA concentration (log transformed) 0.1387 (0.001, 0.2764) 0.048 0.1775 0.1886 (0.0324, 0.3448) 0.019 0.2699
Age –0.0169 (–0.0261, –0.0078) < 0.001 –0.4256 0.0018 (–0.0086, 0.0122) 0.733 0.0470
BMI 0.0206 (–0.0057, 0.0468) 0.122 0.1399 –0.0023 (–0.0312, 0.0265) 0.873 –0.0194
Study site 0.2016 (–0.0098, 0.413) 0.061 0.1629 –0.218 (–0.4489, 0.0129) 0.064 –0.2087
Educational attainment
None/elementary 1 1
Secondary 0.1146 (–0.2084, 0.4375) 0.482 0.0834 –0.4742 (–0.8521, –0.0962) 0.015 –0.4176
High school –0.0347 (–0.3704, 0.3011) 0.838 –0.0275 –0.099 (–0.4865, 0.2885) 0.612 –0.0929
Professional/university 0.0899 (–0.2604, 0.4403) 0.611 0.0542 –0.0379 (–0.4521, 0.3764) 0.856 –0.0268
LDL cholesterol (mg/dL) –0.0024 (–0.006, 0.0012) 0.195 –0.117 0.0016 (–0.0022, 0.0055) 0.407 0.094
Triglycerides (mg/dL) 0.0012 (–0.0002, 0.0025) 0.095 0.1444 –0.0009 (–0.0023, 0.0006) 0.255 –0.1339
Neutrophil% –0.3194 (–0.8618, 0.2229) 0.245 –5.1245 0.3622 (–0.2803, 1.0047) 0.265 6.5463
Lymphocyte% –0.302 (–0.845, 0.2411) 0.272 –4.606 0.3611 (–0.2828, 1.0049) 0.267 6.1452
Monocyte% –0.2982 (–0.8349, 0.2385) 0.272 –1.0051 0.3678 (–0.265, 1.0007) 0.250 1.5245
Eosinophil% –0.3075 (–0.8726, 0.2575) 0.282 –0.8726 0.3624 (–0.2947, 1.0196) 0.275 1.2623
Constant 31.078 (–23.088, 85.244) 0.257 –36.1216 0.264 0
Std, standardized. “Constant” refers to the intercept term in the multiple regression model; it gives the expected log-transformed gene expression level when all other variables in the 
model are set to zero.
Figure 1. Box plot of ESR2 and ESRRA probe intensity by urinary BPA concentration. Boxes extend from 
the 25th to the 75th percentile, horizontal bars represent the median, whiskers indicate the 10th and 90th 
percentiles, and outliers are represented as circles. 
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of BPA exposure on a wider range of adult 
reproductive and somatic tissues merits further 
attention (Goodman et al. 2008). However, 
up to 50% of expression changes in leukocytes 
for highly heritable cis-acting traits are also 
mirrored in other tissues such as adipose tissue, 
making them viable surrogates for exposure of 
other tissues (Emilsson et al. 2008). Human 
adipocytes express both ERβ and ERRα 
(Hugo et al. 2008), and adipocyte explants 
respond to both BPA and 17β-estradiol expo-
sure in the nano  molar range by accumulating 
lipid. Taken together, these results are strongly 
suggestive of specific and targeted bioactivity 
of BPA in vivo, even if the clinical relevance, if 
any, of these findings is not yet clear.
One limitation of this analysis is its 
cross-sectional nature. Virtually all individu-
als are exposed, and because clinical trials to 
administer BPA in human subjects are ethi-
cally unacceptable, collecting longitudinal data 
demonstrating that BPA exposure induces 
gene expression changes in vivo is not cur-
rently achievable.
It is feasible that the increases in gene 
expression that we measured are associated 
with confounding variables that have not been 
accounted for in our models. For example, 
there are time-dependent changes in ERβ 
expression, both on a long-term scale, such 
as in fetal and post  natal development, and in 
short-term oscillations during the circadian 
cycle (Swedenborg et al. 2009). Although it is 
not possible to completely account for circa-
dian cycles, all samples were taken at a similar 
time of day, and we restricted our analysis to 
men rather than women to minimize the influ-
ence of cyclic variation in endogenous hor-
mones. Confounding variables that could affect 
BPA exposure include higher food intakes or 
obesity, which could be accompanied by inci-
dentally higher intakes of BPA (Sharpe 2010). 
Our secondary analyses included adjustment 
for BMI and LDL cholesterol and triglyceride 
concentrations, and these made minimal dif-
ference to the overall results, arguing against 
obesity as an explanation for our findings. We 
found no associations between serum lipids and 
expression intensities of our candidate genes.
Another consideration is that we quan-
tified BPA metabolites in urine, while gene 
expression was measured in blood leuko  cytes. 
BPA ingested in humans is rapidly excreted, so 
urine is considered the most viable biomoni-
toring approach for BPA, as detailed by 
Calafat et al. (2005). Single spot samples are 
limited measures of longer-term exposure, but 
a in study of temporal variability in urinary 
BPA metabolites, Mahalingaiah et al. (2008) 
found that a single spot sample had moder-
ate sensitivity for predicting an individual’s 
tertiary categorization. Nepomnaschy et al. 
(2009) meas  ured stability of BPA over 2-week 
intervals in first voided urine samples from 
60 women and found a Spearman correlation 
of 0.5, indicating that within-individual BPA 
exposures were generally stable over periods 
of weeks. They also showed that the stability 
of BPA in long-term frozen samples is good. 
The stability of free BPA in urine was also 
confirmed by Ye et al. (2011).
The mean BPA concentration in our study 
was 3.65 ng/mL, and assuming an average 
24-hr urine volume of 1,600 mL in adult men 
(Galloway et al. 2010), a 100% excretion rate, 
and a total blood volume of 6 L, the estimated 
concentration of BPA in the blood was in 
the low nanogram per milliliter range. The 
in vitro IC50 (half-maximal inhibitory con-
centration) for human ERβ receptor binding 
of BPA is in the micro  molar range (Matthews 
et al. 2001), which would imply low ER occu-
pancy rates. Given that functional effects of 
BPA on nuclear receptor expression have also 
been reported in both animal and human cells 
at this concentration, in vitro measurement 
may not be indicative of the in vivo situation 
where differential binding to carrier proteins 
and receptors may occur. There are no in vivo 
data on the rate at which BPA is converted 
to BPA-monoglucuronide and excreted from 
the body, only estimates, and because BPA 
is lipophilic with a log octanol–water parti-
tion coefficient (Kow) of 2.2–3.82, distribu-
tion to lipid-rich tissues is a possibility. This 
suggestion is supported by population-based 
half-lives for BPA calculated by Stahlhut et al. 
(2009) to be significantly longer than previous 
predictions of 6 hr.
The major metabolite of BPA, BPA-
monoglucuronide, has no estrogenic activity, 
but oxidative cleavage of BPA to form the 
estrogenically active metabolite 4-methyl-2,4-
bis(4-hydroxyphenyl)pent-1-ene (MBP) has 
been observed in rat liver. Okuda et al. (2010) 
reported that MBP was 500-fold more potent 
than BPA itself in inducing dose-  dependent 
changes in expression of ERα and ERβ 
mRNA. The signifi  cance of this metabolite in 
humans is not yet known. However, a com-
parison of the phase 1 metabolism of BPA in 
rat and human liver micro  somes identified the 
oxidation product BPA-catechol to be a minor 
(~ 10%) metabolite in both species. BPA-
catechol is considered to be a weak estrogen 
(Nakagawa and Suzuki 2001), suggesting that 
further investigation of the phase 1 metabo-
lism of BPA in humans and the estrogenic 
potency of all metabolites is merited (Ye et al. 
2011).
Conclusion
We provide the first report of associations 
between BPA exposure and in vivo estrogenic 
gene expression in humans. We examined 
in vivo expression of six ER, ERR, and AR 
genes in peripheral blood leuko  cytes from 
96 adult men from the InCHIANTI popula-
tion study. We observed positive associations 
between higher urinary BPA concentrations 
and higher expression of two estrogen-respon-
sive genes, encoding ERβ and ERRα. The asso-
ciations remained statistically significant when 
adjusted for potential confounders, includ-
ing obesity and serum lipid concentrations. 
The individuals in the upper tertile of BPA 
exposure showed 65% higher mean expression 
of the ESR2 (ERβ) gene in peripheral blood 
Figure 2. Cubic regression spline models illustrating the functional form of the relationship between log-transformed urinary BPA concentration and ESR2 (A) and 
ESSRA (B) gene expression. 
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leukocytes than did those in the lower tertile. 
Although the clinical significance of these 
results is not yet known, such activation in 
humans provides evidence that BPA is likely to 
function as a xeno  estrogen in this population-
representative sample of adults. This prompts 
a need for replication and scien  tific follow-up, 
for example, in examining the relationship 
between gene expression changes and protein 
expression and effects of BPA exposure in a 
wider range of estrogen-regulated target tissues.
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